Price
CHART BY
Frequently asked questions
What is Iovance's market capitalization?
The market capitalization of Iovance is $3.16B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Iovance?
Iovance's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.721. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Iovance's stock?
Currently, 9 analysts cover Iovance's stock, with a consensus target price of $9.222. Analyst ratings provide insights into the stock's expected performance.
What is Iovance's revenue over the trailing twelve months?
Over the trailing twelve months, Iovance reported a revenue of $324.91M.
What is the EBITDA for Iovance?
Iovance's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$251.06M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Iovance?
Iovance has a free cash flow of -$296.40M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Iovance have, and what sector and industry does it belong to?
Iovance employs approximately 975 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Iovance's shares?
The free float of Iovance is 393.46M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $3.16B
- EPS (TTM)
- -$0.721
- Free Float
- 393.46M
- Revenue (TTM)
- $324.91M
- EBITDA (TTM)
- -$251.06M
- Free Cashflow (TTM)
- -$296.40M
Pricing
- 1D span
- $6.374$6.999
- 52W span
- $1.765$7.00
Analyst Ratings
The price target is $9.222 and the stock is covered by 9 analysts.
Buy
7
Hold
2
Sell
0
Information
Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
- Employees
- 975
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- IOVA
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet